Heart failure in patients treated with human immunodeficient virus protease inhibitors;Les inhibiteurs de la protéase du VIH favorisent-ils la survenue de syndromes coronaires aigus?

Presse Medicale

Volumn 31, Issue 8, 2002, Pages 343-348

  Barthélémy, Oliver ^a   Escaut, L ^a   Vayre, F ^a   Gallet, B ^a   Pulik, M ^a   Heloire, F ^a   Vittecoq, D ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DYSLIPIDEMIA; ENZYME INHIBITION; FEMALE; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EVENT; MALE; MONITORING; PROGNOSIS; RESPONSIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANGINA PECTORIS; ANGINA, UNSTABLE; CHOLESTEROL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; RITONAVIR; SAQUINAVIR; SMOKING; TIME FACTORS; TRIGLYCERIDES;

EID: 0037006508     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Choosing the best initial therapy for HIV-1 infection
2. Cardiac manifestations of HIV/AIDS. A review of disease spectrum and clinicalmanagement
3. Comparison among acquired immune deficiency syndrome patients with and without clinical evidence of cardiac disease
4. Severe premature coronary artery disease with protease inhibitors
5. Atherogenic dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors
6. « Buffalo hump » in HIV-1 infection
7. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
8. Marked hyperlipidemia on ritonavir therapy
9. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection
10. The mysteries of lipoprotein(a)
11. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men
12. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
13. Complications cardiovasculaires chez les patients infectés par le VIH: Les antiprotéases sont-elles en cause?
14. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: A pilot stud
15. Protease inhibitor-associated hyperglycemia
16. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
17. Diagnosis, prediction and nature course of HIV-1 protease -inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: A cohort study
18. Vascular complications associated with use of HIV protease inhibitors
19. Vascular complications associated with use of HIV protease inhibitors
20. Vascular complications associated with use of HIV protease inhibitors
21. Myocardial infarction in HIV-infected men receiving protease inhibitors
22. Complications cardiaques des médicaments au cours de l'infection par le VIH
23. Thromboembolic disease associated with initiation of protease inhibitor therapy
24. Vascular complications associated with use of HIV protease inhibitors
25. Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E and G, but not M
26. Hemorheology in asymptomatic HIV-infected patients
27. Chronic infections and coronary heart disease: Is there a link?
28. Coronary artery lesions and human immunodeficiency virus infection
29. Herz und AIDS
30. Circulation
31. Reduced reactive hyperemia in HIV-infected patients